Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present results suggest that GSH inhibition is a promising strategy for the treatment of diffuse-type gastric cancers with ARID1A deficiency.
|
31761322 |
2020 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we investigated the prognostic value of ARID1A for gastric cancer and its association with expression of PD-L1 and p53.
|
31043675 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of ARID1A and PIK3CA in gastric cancer were significantly associated with the depth of invasion of gastric cancer.
|
30747208 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ARID1A was expressed heterogeneously in 23 (5.1%) GCs, depicting a black-and-white pattern of negative and positive tumor areas.
|
31704366 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
After ARID1A knockdown in GC cell lines, total and membranous PD-L1 protein, and PD-L1 mRNA levels were increased based on Western blot, flow cytometry, and qRT-PCR, respectively.
|
30664822 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ARID1A mutation of GC was significantly associated with microsatellite instability (MSI) (OR = 24.5, P < 0.001) and EBV infection (OR = 2.6, P = 0.001).
|
28937020 |
2018 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings suggested NF-κB/miR-223-3p/ARID1A axis may link the process of H. pylori-induced chronic inflammation to gastric cancer, thereby providing a new insight into the mechanism underlying H. pylori-associated gastric diseases.
|
29317648 |
2018 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Loss of ARID1A expression was observed in 21.1% of GC (88/417), but was not observed in gastric adenoma tissues or non-neoplastic gastric mucosa tissues.
|
26067140 |
2017 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study demonstrated a significant relationship between deletion of ARID1A expression and poor OS in GC.
|
27354232 |
2016 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
The recent years has seen considerable progress in deciphering the genomic landscape of GC, identifying new molecular components such as ARID1A and RHOA, cellular pathways, and tissue populations associated with gastric malignancy and progression.
|
26073375 |
2015 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overall, 78% of GC cases harbored one clinically relevant GA or more, with the most frequent alterations being found in TP53 (50%), ARID1A (24%), KRAS (16%), CDH1 (15%), CDKN2A (14%), CCND1 (9.5%), ERBB2 (8.5%), PIK3CA (8.6%), MLL2 (6.9%), FGFR2 (6.0%), and MET (6.0%).
|
25882375 |
2015 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that ARID1A expression is reduced in gastric cancer (GC) tissues, which are significantly associated with local lymph node metastasis, tumor infiltration and poor patient prognosis.
|
24293408 |
2014 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in chromatin remodeling genes (ARID1A, MLL3 and MLL) have been found in 47% of GCs.
|
24744582 |
2014 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
It has been proposed that ARID1A is a driver gene, with ARID1A mutations occurring secondary to deregulated mismatch repair mechanism in gastric cancers, representing an alternative oncogenic pathway to p53 alteration.
|
23887303 |
2014 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
CTD_human |
Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer.
|
24816253 |
2014 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Somatic inactivation of FAT4 and ARID1A may thus be key tumorigenic events in a subset of gastric cancers.
|
22484628 |
2012 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the current study, we investigated the expression and prognosis value of ARID1A in primary gastric cancer.
|
22808142 |
2012 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
CTD_human |
Somatic inactivation of FAT4 and ARID1A may thus be key tumorigenic events in a subset of gastric cancers.
|
22484628 |
2012 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two recently published studies identified somatic mutations in ARID1A gene in GC using exome sequencing.
|
22958152 |
2012 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability.
|
22915242 |
2012 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
CTD_human |
The mutation spectrum for ARID1A differs between molecular subtypes of gastric cancer, and mutation prevalence is negatively associated with mutations in TP53.
|
22037554 |
2011 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The mutation spectrum for ARID1A differs between molecular subtypes of gastric cancer, and mutation prevalence is negatively associated with mutations in TP53.
|
22037554 |
2011 |